Since the inception of radionuclide therapies by John Lawrence and Saul Hertz over 80 y ago, little has changed regarding ...

You do not have access to the full text of this article, the first page of the PDF of this article appears above. This article requires a subscription to view the full text. If you have a subscription ...

Journal of Nuclear Medicine August 2026, jnumed.126.272179; DOI: https://doi.org/10.2967/jnumed.126.272179 ...

The Highlights Lecture, presented at the closing session of each SNMMI Annual Meeting, was originated and presented for more than 30 years by Henry N. Wagner, Jr., MD. Beginning in 2010, the duties of ...

In the past decade, an increasing number of approved therapies with various mechanisms of action have become available for metastatic castration-resistant prostate cancer (mCRPC), but the associated ...

Radiopharmaceutical therapy (RPT) delivers protracted, low absorbed dose rate radiation over time, with cellular DNA repair ...

Journal of Nuclear Medicine August 2026, jnumed.126.272655; DOI: https://doi.org/10.2967/jnumed.126.272655 ...

The Nuclear Medicine Global Initiative was formed in 2012 by 13 international organizations to promote human health by advancing the field of nuclear medicine and molecular imaging by supporting the ...

Developing novel radiopharmaceuticals for cancer theranostics has recently attracted extensive interest. Bifunctional chelators are key components of many radiometal-based radiopharmaceuticals. For ...

Elevation of the end-tidal partial pressure of CO2 (PETco2) increases cerebral and myocardial blood flow (MBF), suggesting that it may be a suitable alternative to pharmacologic stress or exercise for ...

Journal of Nuclear Medicine May 2026, jnumed.125.271348; DOI: https://doi.org/10.2967/jnumed.125.271348 ...

WHY IS FAP-TARGETED THERAPY ATTRACTIVE? FAP-positive CAFs are found in more than 90% of epithelial cancers, therefore representing a potential pan-cancer target (6). Targeting FAP to deplete stromal ...